Schroder Adveq cPl Global Management III L.P. 4
4 · Decibel Therapeutics, Inc. · Filed Mar 8, 2021
Insider Transaction Report
Form 4
Schroder Adveq Technology IX S.C.S.
10% Owner
Transactions
- Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)→ Common Stock (524,328 underlying) - Conversion
Series C Preferred Stock
2021-02-17−6,625,001→ 0 total(indirect: See footnote)→ Common Stock (524,328 underlying) - Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote) - Conversion
Common Stock
2021-02-17+524,328→ 524,328 total(indirect: See footnote)
Footnotes (3)
- [F1]The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value per share, on an approximately 12.635:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
- [F2]Held directly by Schroder Adveq Technology IX S.C.S. Schroder Adveq Management Luxembourg S.a.r.l. is the general partner of Schroder Adveq Technology IX S.C.S. Schroder Adveq Management Luxembourg S.a.r.l. disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
- [F3]Held directly by Schroder Adveq cPl Global 2017 - 2019 C.V. Schroder Adveq cPl Global Management III L.P. is the general partner of Schroder Adveq cPl Global 2017 - 2019 C.V. Schroder Adveq cPl Global Management III L.P. disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.